Mapi Pharma receives US patent for multiple sclerosis treatm

[MSUK]

Mapi Pharma, developer of complex bulk Active Pharmaceutical Ingredients (APIs), has been granted a US patent for a long acting depot formulation of glatiramer acetate, which is under the development as a once-a-month treatment for Multiple Sclerosis (MS).... Read More - http://www.ms-uk.org/index.cfm/copaxone